8-K filing — Quantum-Si Inc (QSI)
Filed: 2026-11-18 AccNo: 0001816431-26-000080 Size: 1 MB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Stocks · News reference
Quantum-Si Incorporated announced it has successfully demonstrated the detection of all 20 naturally occurring amino acids in its Proteus development program, meeting its year-end 2026 goal ahead of schedule.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Filed: 2026-11-18 AccNo: 0001816431-26-000080 Size: 1 MB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Analyst Swayampakula Ramakanth of H.C. Wainwright has reaffirmed a Buy rating and a $4 price target for Quantum-Si.
Quantum-Si announced its financial results for the third quarter of 2026, reporting revenue of $212,000 and a net loss of $22.3 million as the company transitions from its Platinum platform to the upcoming Proteus platform.
Quantum-Si Incorporated announced it will report Q3 2026 financial results and provide a business update on November 5, 2026, with a conference call hosted by President and CEO Jeff Hawkins and CFO Jeff Keyes at 4:30 PM ET. The company will webcast the event live on its investor relations website.